Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

William Kevin Kelly

Genitourinary Oncology Service

Departments of Medicine

Memorial Sloan-Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University

New York

USA

[email]@mskcc.org

Name/email consistency: high

[Claim this account]

Affiliations

Genitourinary Oncology Service, Departments of Medicine, Memorial Sloan-Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, USA. 2003 - 2005
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center, and Department of Medicine, USA. 2000 - 2003
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, N.Y. 10021, USA. 1998 - 2002

References

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. Kelly, W.K., O'Connor, O.A., Krug, L.M., Chiao, J.H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J.P., Schwartz, L., Richardson, S., Chu, E., Olgac, S., Marks, P.A., Scher, H., Richon, V.M. J. Clin. Oncol. (2005) [Pubmed]
Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer. Kelly, W.K., Zhu, A.X., Scher, H., Curley, T., Fallon, M., Slovin, S., Schwartz, L., Larson, S., Tong, W., Hartley-Asp, B., Pellizzoni, C., Rocchetti, M. Clin. Cancer Res. (2003) [Pubmed]
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Kelly, W.K., Richon, V.M., O'Connor, O., Curley, T., MacGregor-Curtelli, B., Tong, W., Klang, M., Schwartz, L., Richardson, S., Rosa, E., Drobnjak, M., Cordon-Cordo, C., Chiao, J.H., Rifkind, R., Marks, P.A., Scher, H. Clin. Cancer Res. (2003) [Pubmed]
Novel trial designs: which agents and how do we test them?. Kelly, W.K. Urology (2002) [Pubmed]
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. Kelly, W.K., Curley, T., Slovin, S., Heller, G., McCaffrey, J., Bajorin, D., Ciolino, A., Regan, K., Schwartz, M., Kantoff, P., George, D., Oh, W., Smith, M., Kaufman, D., Small, E.J., Schwartz, L., Larson, S., Tong, W., Scher, H. J. Clin. Oncol. (2001) [Pubmed]
Chemotherapy for androgen- independent prostate cancer: myth or reality. Kelly, W.K., Slovin, S.F. Curr. Oncol. Rep (2000) [Pubmed]
Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer. Kelly, W.K. Eur. Urol. (1998) [Pubmed]

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.